MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the…

Overview of attention for article published in BMC Cancer, August 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,078 followers.

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG) https://t.co

19 Aug 2021

Reply Repost Favourite

19 Aug 2021

Reply Repost Favourite

New article: MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian… https://t.co/081M7i6pze #colorectalc

19 Aug 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.